Download Library

Download Library

Document Type
Genmab 2018 ASH Data Review
Genmab 2018 ASH Data Review
Articles of association dated November 20, 2018 – English
Articles of association dated November 20, 2018 – English
Jefferies European Healthcare Conference - November 2018
Jefferies European Healthcare Conference - November 2018
Investor Fact Sheet
Investor Fact Sheet
Genmab Q3 2018 Results Presentation
Genmab Q3 2018 Results Presentation
Genmab Third Quarter 2018 Results Podcast
Genmab Third Quarter 2018 Results Podcast
Interim Report for the First Nine Months of 2018
Interim Report for the First Nine Months of 2018
Genmab's 2018 Capital Markets Day - September 26, 2018
Genmab's 2018 Capital Markets Day - September 26, 2018
Genmab Investor Presentation - September 12, 2018
Genmab Investor Presentation - September 12, 2018
Investor Presentation, August 2018
Investor Presentation, August 2018
Genmab Second Quarter 2018 Results Podcast
Genmab Second Quarter 2018 Results Podcast
Interim Report for the First Half 2018
Interim Report for the First Half 2018
Genmab 2018 Second Quarter Results Presentation
Genmab 2018 Second Quarter Results Presentation
Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Elderly (greater than or equal to 75 Years of age) Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplantation (ALCYONE) - EHA Oral Presentation - June 2018 (Cavo)
Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Elderly (greater than or equal to 75 Years of age) Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplantation (ALCYONE) - EHA Oral Presentation - June 2018 (Cavo)
Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients - EHA Oral Presentation - June 2018 (Casneuf)
Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients - EHA Oral Presentation - June 2018 (Casneuf)
Articles of Association - June 7 2018 - English
Articles of Association - June 7 2018 - English
Subcutaneous Daratumumab (DARA SC) + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of ANDROMEDA - EHA Poster Presentation - June 2018 (Merlini)
Subcutaneous Daratumumab (DARA SC) + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of ANDROMEDA - EHA Poster Presentation - June 2018 (Merlini)
Daratumumab, Carfilzomib and Dexamethasone (D-Kd) in Lenalidomide-refractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 - EHA Poster Presentation - June 2018 (Moreau)
Daratumumab, Carfilzomib and Dexamethasone (D-Kd) in Lenalidomide-refractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 - EHA Poster Presentation - June 2018 (Moreau)
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO) - EHA Poster Presentation - June 2018 (San-Miguel)
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO) - EHA Poster Presentation - June 2018 (San-Miguel)
Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplantation (ALCYONE) - EHA Poser Presentation - June 2018 (Cavo)
Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplantation (ALCYONE) - EHA Poser Presentation - June 2018 (Cavo)
Genmab Investor Presentation - June 2018
Genmab Investor Presentation - June 2018
Phase 3 study of subcutaneous Daratumumab vs active monitoring in patients with high-risk Smoldering Multiple Myeloma: AQUILA - ASCO poster - June 2018 (Rajkumar)
Phase 3 study of subcutaneous Daratumumab vs active monitoring in patients with high-risk Smoldering Multiple Myeloma: AQUILA - ASCO poster - June 2018 (Rajkumar)
Daratumumab plus Bortezomib-Melphalan-Prednisone in elderly (greater than or equal to 75 y) patients with newly diagnosed Multiple Myeloma ineligible for transplantation (ALCYONE) (MMY3007) - ASCO poster - June 2018 (Cavo)
Daratumumab plus Bortezomib-Melphalan-Prednisone in elderly (greater than or equal to 75 y) patients with newly diagnosed Multiple Myeloma ineligible for transplantation (ALCYONE) (MMY3007) - ASCO poster - June 2018 (Cavo)
Phase 3 study of subcutaneous vs intravenous DARA administration in pts with relapsed or refractory Multiple Myeloma: COLUMBA (MMY3012) - ASCO poster - June 2018 (Usmani)
Phase 3 study of subcutaneous vs intravenous DARA administration in pts with relapsed or refractory Multiple Myeloma: COLUMBA (MMY3012) - ASCO poster - June 2018 (Usmani)
Phase 2, multicenter trial of tisotumab vedotin in previously treated, recurrent or metastatic cervical cancer - ASCO poster - June 2018 (Coleman)
Phase 2, multicenter trial of tisotumab vedotin in previously treated, recurrent or metastatic cervical cancer - ASCO poster - June 2018 (Coleman)
Subcutaneous Daratumumab plus Cyclophosphamide, Bortezomib, and Dexamethasone in patients with newly diagnosed Amyloid Light Chain Amyloidosis: Safety run-in results of ANDROMEDA (AMY3001) - ASCO poster discussion - June 2018 (Comenzo)
Subcutaneous Daratumumab plus Cyclophosphamide, Bortezomib, and Dexamethasone in patients with newly diagnosed Amyloid Light Chain Amyloidosis: Safety run-in results of ANDROMEDA (AMY3001) - ASCO poster discussion - June 2018 (Comenzo)